One case of breast hyperplasia caused by digoxin tablets

doi:10.19803/j.1672-8629.20210979

Abstract

Abstract: Objective To study one case of breast hyperplasia induced by digoxin tablets in order to provide reference for clinical prevention and treatment of related adverse reactions. Methods The process of treating one patient who had developed breast hyperplasia after taking digoxin tablets was analyzed. The mechanism by which digoxin tablets caused breast hyperplasia was investigated and the possibility of involvement of other drugs was ruled out. Results The patient had bilateral breast hyperplasia after taking digoxin. After the drug was discontinued and other medications were used for one month, breast discomfort decreased. Conclusion Breast hyperplasia caused by digoxin tablets may be related to the estrogen-like effect of digitalis drugs, so regular breast examination is required during medication. It is also important to guard against other serious adverse reactions caused by digoxin tablets.

Key words: digoxin, breast hyperplasia, breast development, estrogen, androgen, adverse drug reactions

CLC Number:

R994.11

OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying. One case of breast hyperplasia caused by digoxin tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.

References

[1] Heart Failure Group of Cardiology Branch of Chinese Medical Association, Heart Failure Professional Committee of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiovascular Diseases. Chinese Heart Failure Diagnosis and Treatment Guidelines 2018[J]. Chinese Journal of Heart Failure and Cardiomyopathy(中华心力衰竭和心肌病杂志), 2018, 2(4): 196-225.
[2] CHEN C, YOU L.Diagnosis and treatment of digoxin in patients with chronic heart failure[J]. Health Vision(健康大视野), 2018(11): 200.
[3] FU HY.Monitoring results of digoxin blood concentration and analysis of adverse reactions in 219 cases[J]. Laboratory Medicine and Clinic(检验医学与临床), 2016, 13(z1): 57-59.
[4] XU CF.The effect of levosimendan and digoxin in the treatment of chronic heart failure and its adverse reactions[J]. Contemporary Medicine(当代医学), 2021, 27(25): 32-34.
[5] MACLEOD-GLOVER N, MINK M, YAREMA M, et al.Digoxin toxicity Case for retiring its use in elderly patients?[J]. Canadian Family Physician, 2016, 62(3): 223-228.
[6] LIN Y, MU DL.Advances in surgical treatment of gynecomastia[J]. Chinese Journal of Aesthetic Plastic Surgery(中国美容整形外科杂志), 2021, 32(6): 344-347.
[7] GAO Z, JING CF.Analysis of the causes of mammary gland hyperplasia in a male patient with heart failure by clinical pharmacists[J]. Journal of Pharmacy Practice(药学实践杂志), 2019, 37(5): 470-472.
[8] COOPEY SB, KARTAL K, LI C, et al.Atypical ductal hyperplasia in men with gynecomastia: What is their breast cancer risk?[J]. Breast Cancer Research and Treatment, 2019, 175(1): 1-4.
[9] KANAKIS G A, NORDKAP L, BANG A K, et al.EAA clinical practice guidelines-gynecomastia evaluation and management[J]. Andrology, 2019, 7(6): 778-793.
[10] BOWMAN JD, KIM H, BUSTAMANTE JJ.Drug-induced gynecomastia[J]. Pharmacotherapy, 2012, 32(12): 1123-1140.
[11] DEEPINDER F, BRAUNSTEIN G D.Drug-induced gynecomastia: an evidence-based review[J]. Expert Opin Drug Saf, 2012, 11(5): 779-795.
[12] LI L, LI Q, WANG JH, et al.Analysis of 23 cases of digitalis overdose related to Qili Qiangxin capsules[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(6): 357-359, 362.
[13] PENG HL, GE CQ, HE ZH, et al.Two cases of gynecomastia induced by digoxin[J]. Chinese Journal of Gerontology(中华老年医学杂志), 1999, 18(6): 374.
[14] MOHAMMAD MK, KASIJAGADEESH M, KUMARASWAMY RC.Spironolactone/ Digoxin-induced gynecomastia(a comparative case study)[J]. World Journal of Pharmaceutical Research(世界药物研究杂志), 2014, 3(6): 1014-1018.
[15] WANG Y, WANG PF, LIU GD, et al.A case of male breast hyperplasia caused by spironolactone tablets[J]. Chinese Pharmacist(中国药师), 2019, 22(7): 1315.
[16] TIAN LX, JIA XX.Analysis of a case of gynecomastia caused by spironolactone[J]. Chinese Health Nutrition(中国保健营养), 2016, 26(14): 147-148.
[17] Measures for the reporting and monitoring of adverse drug reactions[J]. Communiqué of the Ministry of Health of the People’s Republic of China, 2011, (6): 1-10.
[18] Chinese Pharmacological Society.Proceedings of the 2011 National Medical Academic Papers Exchange Conference(2011年全国医药学术论坛交流会暨临床药学与药学服务研究进展培训班论文集)[C]. Taiyuan: 2011.
[19] THIRUCHELVAM P, WALKER J N, ROSE K, et al.Gynaecomastia[J]. BMj-British Medical Journal, 2016, 354: i4833.